Streetbeat News

Products Services

PLUG

Plug Power's stock is trading higher following the announcement of winning three electrolyzer contracts.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:42 am

BBIO

BridgeBio Pharma presented positive data from six participants in its Phase 1/2 clinical trial of BBP-812, an investigational gene therapy for the treatment of Canavan disease, at the 2023 ASGCT Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:32 am

PLUG

Plug Power has secured three electrolyzer deals for European green hydrogen projects in hard-to-decarbonize industries. These deals will help expand Plug's presence in the European market and support the growth of green hydrogen production.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:16 am

MOB

Mobilicom's product suite has been selected for deployment in autonomous and remote-controlled electric vehicle (EV) platforms for homeland security and defense applications.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:11 am

AVTR

Avantor and Labguru have collaborated to integrate Avantor's Inventory Management software with Labguru's Electronic Lab Notebook, providing scientists with single-source access to high-quality products from the lab bench.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:10 am

CMP

F

Compass Minerals has signed a binding multiyear agreement to supply Ford Motor with battery-grade lithium carbonate, a key component in electric vehicle batteries.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:10 am

NBSE

Neubase Therapeutics announced preclinical safety and efficiency data for its Stealth Editors Development Program, demonstrating gene editing with a non-immunogenic system.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:08 am

AVRO

NVS

AVROBIO has agreed to sell its cystinosis gene therapy program to Novartis for $87.5 million. The deal will allow AVROBIO to focus on its core pipeline and Novartis to expand its gene therapy portfolio.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:06 am

MIST

Milestone Pharmaceuticals (NASDAQ:MIST) announced promising data from an ad hoc analysis of a subset of patients experiencing atrial fibrillation with rapid ventricular rate (AFib-RVR) in the NODE-303 study, which evaluated etripamil, the Company's investigational calcium channel blocker.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:06 am

RDHL

Redhill Biopharma has terminated its RHB-204 U.S. Phase 3 study for non-tuberculosis mycobacteria disease due to low accrual rate. The company will shift resources to advance oral RHB-107's late-stage development for COVID-19 and focus on key pipeline catalysts and revenue-generating product acquisition.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:06 am